Vestronidase alfa
| Clinical data | |
|---|---|
| Trade names | Mepsevii |
| Other names | Vestronidase alfa |
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C3308H4996N874O940S16 |
| Molar mass | 72562.49 g·mol−1 |
Vestronidase alfa-vjbk (trade name Mepsevii) is a drug for the treatment of Sly syndrome. It is a recombinant form of the human enzyme beta-glucuronidase. In the United States, it was approved in November 2017.[2]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "FDA approves treatment for rare genetic enzyme disorder" (Press release). Food and Drug Administration.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |